Table 1 Baseline characteristics and clinical demographics of the study population
All patients (n = 197) | Patients with CACS ≤10 (n = 156) | Patients with CACS > 10 (n = 41) | |
|---|---|---|---|
Clinical characteristics | |||
Age, years (±SD) | 63 ± 11.4 | 62.3 ± 11.3 | 66.1 ± 11.1 |
Males | 125 (63.4%) | 96 (61.5%) | 29 (70.7%) |
BMI, kg/m2 (±SD) | 25.7 ± 3.3 | 25.8 ± 3.4 | 25.1 ± 3.1 |
Hypercholesterolemia | 85 (43%) | 72 (46.1%) | 13 (31.7%) |
Hypertension | 113 (57.3%) | 92 (58.9%) | 21 (51.2%) |
Smoking | 60 (30.4%) | 48 (30.7%) | 12 (29.3%) |
Family history of CAD | 35 (17.8%) | 26 (16.7%) | 9 (21.9%) |
Baseline CAC Score | 12.5 [0, 102.5] | 6.5 [0, 9.8] | 29.2 [11.3, 102.5] |
Pretest likelihood of CAD | |||
Low | 57 | 45 | 12 |
Moderate | 111 | 89 | 22 |
High | 29 | 22 | 7 |
Medical therapy | |||
Aspirin | 110 (52.7%) | 82 (52.5%) | 22 (53.7%) |
Statins | 71 (36.0%) | 53 (34.0%) | 18 (43.9%) |
Β-blocker | 81 (41.1%) | 57 (46.5%) | 24 (58.5%) |
Calcium channel blocker | 59 (29.9%) | 46 (29.4%) | 13 (31.7%) |
CAD-RADS reporting data | |||
CAD-RADS 0 | 36 | 30 | 7 |
CAD-RADS 1 | 51 | 41 | 13 |
CAD-RADS 2 | 100 | 77 | 19 |
CAD-RADS 3 | 10 | 8 | 2 |